Director and 10% Owner Buys $1.2M in Ultralife Stock Post-Earnings
ULBI sits 78% above its 52-week low of $4.07 on elevated volume (2.9× avg).
Summary
A Director and 10% owner of Ultralife Corp, Bradford T. Whitmore, significantly increased his stake by purchasing over $1.19 million in common stock following recent negative earnings news.
Key Events · Ownership and Investor Activity · ULBI
-
Director and 10% Owner Purchase
Bradford T. Whitmore, a Director and 10% owner of Ultralife Corp, acquired 187,512 shares of common stock through open market purchases.
-
Significant Investment
The total value of these purchases amounted to $1,196,909, representing a substantial increase in his indirect holdings.
-
Post-Earnings Timing
These transactions took place between March 12 and March 16, 2026, following the company's report of a Q4 net loss and impairment charge on March 10, 2026.
Analysis · ULBI · Manufacturing
The acquisition of nearly $1.2 million in common stock by Bradford T. Whitmore, who serves as both a Director and a 10% owner, represents a significant vote of confidence in Ultralife Corp. This substantial investment, totaling 187,512 shares, is particularly notable as it occurred shortly after the company reported a Q4 net loss and a significant impairment charge on March 10, 2026. The timing suggests strong conviction in the company's long-term prospects despite recent financial setbacks, potentially signaling a belief that the stock is undervalued.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ULBI was trading at $7.24 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $116.7M. The 52-week trading range was $4.07 to $9.52. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.